相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as Isoglycemic Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes
Irfan Vardarli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Effect of Endogenous GLP-1 on Insulin Secretion in Type 2 Diabetes
Marzieh Salehi et al.
DIABETES (2010)
Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes
J. Rosenstock et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Dipeptidyl Peptidase-4 Inhibition by Vildagliptin and the Effect on Insulin Secretion and Action in Response to Meal Ingestion in Type 2 Diabetes
Chiara Dalla Man et al.
DIABETES CARE (2009)
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
Ralph A. DeFronzo et al.
DIABETES CARE (2009)
One-year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients A randomized, controlled trial
Mathijs C. Bunck et al.
DIABETES CARE (2009)
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
M. Jadzinsky et al.
DIABETES OBESITY & METABOLISM (2009)
Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes
James Mu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
A. R. Chacra et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes
Bo Ahren et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 Diabetes
David A. D'Alessio et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone
Priscilla Hollander et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia
W. A. Scherbaum et al.
DIABETES OBESITY & METABOLISM (2008)
Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia
W. A. Scherbaum et al.
DIABETES OBESITY & METABOLISM (2008)
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2008)
Characterization of the influence of vildagliptin on model-assessed beta-cell function in patients with type 2 diabetes and mild hyperglycemia
Andrea Mari et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes
Koichiro Azuma et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Acute insulin responses to glucose and arginine as predictors of β-cell secretory capacity in human islet transplantation
Michael R. Rickels et al.
TRANSPLANTATION (2007)
The role of α-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications
Beth Elaine Dunning et al.
ENDOCRINE REVIEWS (2007)
Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and β-cell function in patients with type 2 diabetes
R. Brazg et al.
DIABETES OBESITY & METABOLISM (2007)
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner et al.
DIABETES CARE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Bernard Charbonnel et al.
DIABETES CARE (2006)
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
Gary A. Herman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes
James Mu et al.
DIABETES (2006)
Measurements of insulin responses as predictive markers of pancreatic β-cell mass in normal and β-cell-reduced lean and obese Gottingen minipigs in vivo
MO Larsen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2006)
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes
A Mari et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year
B Ahrén et al.
DIABETES CARE (2005)
Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B
L Li et al.
DIABETOLOGIA (2005)
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
B Ahrén et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Desensitization of insulin secretion by depolarizing insulin secretagogues
I Rustenbeck et al.
DIABETES (2004)
Use and abuse of HOMA modeling
TM Wallace et al.
DIABETES CARE (2004)
Glucagon-like peptide 1 agonists and the development and growth of pancreatic β-cells
JF List et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
AIRarg and AIRgluc as predictors of insulin secretory reserve
RP Robertson
TRANSPLANTATION PROCEEDINGS (2004)
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus
T Vilsboll et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats
JA Pospisilik et al.
DIABETES (2003)
The influence of GLP-1 on glucose-stimulated insulin secretion -: Effects on β-cell sensitivity in type 2 and nondiabetic subjects
LL Kjems et al.
DIABETES (2003)
Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice
MK Reimer et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002)
Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide
CF Deacon et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
分享论文
